בניית אתרים בניית אתרים Media4u

ברכיתרפיה

Matzkin H, Hardeman S, Soloway MS
Transitional cell carcinoma of the prostate
Urol, 1991;146:1207-1212

Matzkin H, Lewison O, Ayalon D, Braf Z
Prostatic markers in the follow up of patients with advanced prostatic carcinoma
treated with GnRH analogue
Cancer, 1989;63:1287-1291

Matzkin H, Greenstein A, Kaver I, Braf Z
GnRH analogue in advanced prostatic carcinoma - prolonged follow-up
Isr J Med Sci 1989;25:388-392

 
Matzkin H, Greenstein A, Braf Z
Clinical importance of prostatic measurements in the follow up of patients
treated with GnRH analogue for advanced prostatic cancer
Urology 1990;36:214-218

Soloway MS, Matzkin H
Adenocarcinoma of the prostate: Current concepts in the diagnosis
and management
Fam Pract Recert 1991;13:33-52
Matzkin H, Hardeman S, Soloway MS
Transitional cell carcinoma of the prostate
Urol, 1991;146:1207-1212

Rangel C Matzkin H, Soloway MS
Experience with weekly adriamycin in hormone refractory stage D2
prostate cancer
Urology 1992;39:577-582

Matzkin H, Soloway MS
Response to second line hormonal manipulation monitored by serum PSA
in stage D2 prostate carcinoma patients
Urology 1992;40:78-80

Goldray D, Weizman Y, Jaccard N, Merdler C, Chen J, Matzkin H
Decreased bone density in elderly men treated with the GnRH agonist
decapeptyl
J Clin Endocrinol Metab, 1993;76:288-290

Matzkin H, Chen J, Weisman Y, Goldray D, Pappas F, Jaccard N, Braf Z
Prolonged treatment with finasteride, a 5-alpha reductase inhibitor does not
affect bone density and metabolism
Clin Endocrinol, 1992;37:432-436

Matzkin H, Eber H, Todd B, van der Zwaag R, Soloway MS
Prognostic significance of changes in prostate specific markers in endocrine
treatment of stage D2 prostate cancer
Cancer, 1992;70:2032-2038

 
Matzkin H, Soloway MS
Immunohistochemical evidence of the existence and localization of aromatase in
prostatic tissues
Prostate, 1992;21:309-314

Matzkin H, Rangel MC, Soloway MS
Relapse on endocrine treatment in patients with stage D2 prostate cancer
- does second-line therapy affect survival
Urology, 1993;41:144-148

Matzkin H, Soloway MS, Schellhammer P, Chodak J, Smith JA, Caplan R,
Keannelly D
Prognostic factors in stage D2 prostate cancer treated with a pure non-steroidal
antiandrogen
Cancer 1993;72:1286-1290

Matzkin H, Perito P, Soloway MS
Prognostic factors in metastatic prostate cancer
Cancer 1993;72 (suppl):3788-3792

Matzkin H, Soloway MS
Cigarette smoking - a review of possible associations with benign prostatic
hyperplasia and prostate cancer
Prostate, 1993;22:277-290

Soloway MS, Matzkin H
Anti-androgens as monotherapy in advanced prostatic carcinoma
Cancer, 1993;71(Suppl):1083-1088

Matzkin H, Patel JV, Altwein JE, Soloway MS
Stage Tla prostate cancer - a review
Urology 1994;43:11-21

Matzkin H, Braf Z
Complete androgen blocade in the treatment of metastatic
prostate cancer-A review
Harefuah 1994;126:260-263

Laufer M, Matzkin H, Braf Z
Screening for prostatic cancer: Is it appropriate or not
Harefuah 1995;129:39-43

Gilad E, Laudon M, Matzkin H, Pick E, Sofer M, Braf Z, Zisapel N:
Functional melatonin receptors in human prostate epithelial cells.
Endocrinology 1996;137:1412-1417.

Matzkin H, Laufer M, Chen J, Hareuveni M, Braf Z
Effect of elective prolonged urethral catheterization on serum prostate-specific
antigen concentration
Urology 1996; 48:63-66

Matzkin H, Kaver I, Merimsky O
Brachytherapy for prostate cancer - current status
Harefuah 1998;134:947-952

Gilad E, Laufer M, Matzkin H, Zisapel N
Melatonin receptors in PC3 human prostate human cells
J. Pineal Res. 1999;26;211-220

Matzkin H, Kaver I, Stenger A, Agai R, Asna N, Merimsky O
I125 Prostate brachytherapy – Short term results of the first 150 pts. in Israel
Harefuah 2001
Matzkin H, Mabjeesh N, Stenger A, Agai R, Chen J, Inbar M:
Brachytherapy combined with external beam radiation in localized prostate cancer
Harefua 2006:145;8-12.

 

 

סרטן הערמונית | ביופסיה | פרוסטטה| פרוסטטה מוגדלת| טיפול בסרטן הערמונית | ניתוח פרוסטטה | ביופסיה של הערמונית| בדיקת ביופסיה

Copyright 2001. All right reserved ©